Pharmacogenomics of cholesterol-lowering therapy

Vascular Pharmacology

Volumn 44, Issue 2, 2006, Pages 75-89

  Schmitz, Gerd ^a   Langmann, Thomas ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

HMG CoA reductase inhibitors; Pharmacogenetics; Pharmacogenomics; Polymorphisms

Indexed keywords

AMINOTRANSFERASE; ATORVASTATIN; BEZAFIBRATE; BILE ACID SEQUESTRANT; CREATINE KINASE; DIGOXIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; MEVINOLIN; MIBEFRADIL; NICOTINIC ACID; PRAVASTATIN; RESIN; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; AMINOTRANSFERASE BLOOD LEVEL; CONSTIPATION; CREATININE BLOOD LEVEL; DNA SEQUENCE; DRUG EFFICACY; ERECTILE DYSFUNCTION; FLUSHING; GALLSTONE; GENE MUTATION; GENE TARGETING; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; LIPID METABOLISM; LIPOPROTEIN METABOLISM; METABOLIC DISORDER; MYOPATHY; PANCREATITIS; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

APOLIPOPROTEINS E; CARDIOVASCULAR DISEASES; CARRIER PROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CLINICAL TRIALS; GENETIC PREDISPOSITION TO DISEASE; GLYCOPROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MUSCULAR DISEASES; PHARMACOGENETICS; POLYMORPHISM, GENETIC;

EID: 30544450531     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2005.07.012     Document Type: Review

References (154)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group N. Engl. J. Med. 339 1998 1349 1357
3. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study Circulation 102 2000 21 27
4. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study Lancet 357 2001 905 910
5. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
6. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
7. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
8. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
9. B.F. Asztalos, M. Batista, K.V. Horvath, C.E. Cox, G.E. Dallal, J.S. Morse, G.B. Brown, and E.J. Schaefer Change in alpha1 HDL concentration predicts progression in coronary artery stenosis Arterioscler. Thromb. Vasc. Biol. 23 2003 847 852
10. V.G. Athyros, A.A. Papageorgiou, and A.G. Kontopoulos Statin-fibrate combinations in patients with combined hyperlipedemia Atherosclerosis 155 2001 263 264
11. J. Auer, R. Berent, and B. Eber Lessons learned from statin trials Clin. Cardiol. 24 2001 277 280
12. J.T. Backman, C. Kyrklund, K.T. Kivisto, J.S. Wang, and P.J. Neuvonen Plasma concentrations of active simvastatin acid are increased by gemfibrozil Clin. Pharmacol. Ther. 68 2000 122 129
13. J.T. Backman, C. Kyrklund, M. Neuvonen, and P.J. Neuvonen Gemfibrozil greatly increases plasma concentrations of cerivastatin Clin. Pharmacol. Ther. 72 2002 685 691
14. S.K. Baker Molecular clues into the pathogenesis of statin-mediated muscle toxicity Muscle Nerve 31 2005 572 580
15. S.K. Baker, and M.A. Tarnopolsky Statin myopathies: pathophysiologic and clinical perspectives Clin. Invest. Med. 24 2001 258 272
16. C.M. Ballantyne, J.A. Herd, E.A. Stein, L.L. Ferlic, J.K. Dunn, A.M. Gotto Jr., and A.J. Marian Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy J. Am. Coll. Cardiol. 36 2000 1572 1578
17. O. Barbier, I.P. Torra, Y. Duguay, C. Blanquart, J.C. Fruchart, C. Glineur, and B. Staels Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis Arterioscler. Thromb. Vasc. Biol. 22 2002 717 726
18. F. Basso, G.D. Lowe, A. Rumley, A.D. McMahon, and S.E. Humphries Interleukin-6-174G > C polymorphism and risk of coronary heart disease in West of Scotland coronary prevention study (WOSCOPS) Arterioscler. Thromb. Vasc. Biol. 22 2002 599 604
19. H.E. Bays, P.B. Moore, M.A. Drehobl, S. Rosenblatt, P.D. Toth, C.A. Dujovne, R.H. Knopp, L.J. Lipka, A.P. Lebeaut, B. Yang, L.E. Mellars, C. Cuffie-Jackson, and E.P. Veltri Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies Clin. Ther. 23 2001 1209 1230
20. S.L. Beaird HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles J. Am. Pharm. Assoc. (Wash.) 40 2000 637 644
21. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 2004 III50 III57
22. K.E. Berge Sitosterolemia: a gateway to new knowledge about cholesterol metabolism Ann. Med. 35 2003 502 511
23. D.J. Betteridge Lipid-lowering trials in diabetes Curr. Opin. Lipidol. 12 2001 619 623
24. S.M. Boekholdt, W.R. Agema, R.J. Peters, A.H. Zwinderman, E.E. van der Wall, P.H. Reitsma, J.J. Kastelein, and J.W. Jukema Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events Circulation 107 2003 2416 2421
25. K. Bogman, A.K. Peyer, M. Torok, E. Kusters, and J. Drewe HMG-CoA reductase inhibitors and P-glycoprotein modulation Br. J. Pharmacol. 132 2001 1183 1192
26. P.F. Bray, C.P. Cannon, P. Goldschmidt-Clermont, L.A. Moye, M.A. Pfeffer, F.M. Sacks, and E. Braunwald The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction Am. J. Cardiol. 88 2001 347 352
27. B.G. Brown, X.Q. Zhao, A. Chait, L.D. Fisher, M.C. Cheung, J.S. Morse, A.A. Dowdy, E.K. Marino, E.L. Bolson, P. Alaupovic, J. Frohlich, and J.J. Albers Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N. Engl. J. Med. 345 2001 1583 1592
28. H.C. Bucher, L.E. Griffith, and G.H. Guyatt Systematic review on the risk and benefit of different cholesterol-lowering interventions Arterioscler. Thromb. Vasc. Biol. 19 1999 187 195
29. J.F. Carlquist, J.B. Muhlestein, B.D. Horne, N.I. Hart, T.L. Bair, H.O. Molhuizen, and J.L. Anderson The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease Am. Heart J. 146 2003 1007 1014
30. R. Carmena, G. Roederer, H. Mailloux, S. Lussier-Cacan, and J. Davignon The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism Metabolism 42 1993 895 901
31. M.J. Chapman, G. Assmann, J.C. Fruchart, J. Shepherd, and C. Sirtori Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C Curr. Med. Res. Opin. 20 2004 1253 1268
32. D.I. Chasman, D. Posada, L. Subrahmanyan, N.R. Cook, V.P. Stanton Jr., and P.M. Ridker Pharmacogenetic study of statin therapy and cholesterol reduction JAMA 291 2004 2821 2827
33. S. Chen, N. Tsybouleva, C.M. Ballantyne, A.M. Gotto Jr., and A.J. Marian Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study Pharmacogenetics 14 2004 61 71
34. G. Chinetti, J.C. Fruchart, and B. Staels Peroxisome proliferator- activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation Inflamm. Res. 49 2000 497 505
35. U. Christians, W. Jacobsen, and L.C. Floren Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Ther. 80 1998 1 34
36. A. Corsini, S. Bellosta, R. Baetta, R. Fumagalli, R. Paoletti, and F. Bernini New insights into the pharmacodynamic and pharmacokinetic properties of statins Pharmacol. Ther. 84 1999 413 428
37. M.H. Davidson, and P.P. Toth Comparative effects of lipid-lowering therapies Prog. Cardiovasc. Dis. 47 2004 73 104
38. H.R. Davis Jr., L.J. Zhu, L.M. Hoos, G. Tetzloff, M. Maguire, J. Liu, X. Yao, S.P. Iyer, M.H. Lam, E.G. Lund, P.A. Detmers, M.P. Graziano, and S.W. Altmann Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis J. Biol. Chem. 279 2004 33586 33592
39. G.J. de Grooth, K.E. Zerba, S.P. Huang, Z. Tsuchihashi, T. Kirchgessner, R. Belder, P. Vishnupad, B. Hu, A.H. Klerkx, A.H. Zwinderman, J.W. Jukema, F.M. Sacks, J.J. Kastelein, and J.A. Kuivenhoven The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: a prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy J. Am. Coll. Cardiol. 43 2004 854 857
40. P. Delerive, P. Gervois, J.C. Fruchart, and B. Staels Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators J. Biol. Chem. 275 2000 36703 36707
41. M.P. de Maat, J.J. Kastelein, J.W. Jukema, A.H. Zwinderman, H. Jansen, B. Groenemeier, A.V. Bruschke, and C. Kluft - 455G/A polymorphism of the beta-fibrinogen gene is associated with the progression of coronary atherosclerosis in symptomatic men: proposed role for an acute-phase reaction pattern of fibrinogen. REGRESS group Arterioscler. Thromb. Vasc. Biol. 18 1998 265 271
42. M.P. de Maat, J.W. Jukema, S. Ye, A.H. Zwinderman, P.H. Moghaddam, M. Beekman, J.J. Kastelein, A.J. van Boven, A.V. Bruschke, S.E. Humphries, C. Kluft, and A.M. Henney Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis Am. J. Cardiol. 83 1999 852 856
43. K.A. Dornbrook-Lavender, and J.A. Pieper Genetic polymorphisms in emerging cardiovascular risk factors and response to statin therapy Cardiovasc. Drugs Ther. 17 2003 75 82
44. J.R. Downs, M. Clearfield, S. Weis, E. Whitney, D.R. Shapiro, P.A. Beere, A. Langendorfer, E.A. Stein, W. Kruyer, and A.M. Gotto Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
45. P.A. Edwards, and J. Ericsson Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway Annu. Rev. Biochem. 68 1999 157 185
46. H. Elghannam, S. Tavackoli, L. Ferlic, A.M. Gotto Jr., C.M. Ballantyne, and A.J. Marian A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy J. Mol. Med. 78 2000 562 568
47. L. Ernster, and G. Dallner Biochemical, physiological and medical aspects of ubiquinone function Biochim. Biophys. Acta 1271 1995 195 204
48. J.A. Farmer, and G. Torre-Amione Comparative tolerability of the HMG-CoA reductase inhibitors Drug Saf. 23 2000 197 213
49. O.P. Flint, B.A. Masters, R.E. Gregg, and S.K. Durham HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture Toxicol. Appl. Pharmacol. 145 1997 99 110
50. D.J. Freeman, N.J. Samani, V. Wilson, A.D. McMahon, P.S. Braund, S. Cheng, M.J. Caslake, C.J. Packard, and D. Gaffney A polymorphism of the cholesteryl ester transfer protein gene predicts cardiovascular events in non-smokers in the West of Scotland Coronary Prevention Study Eur. Heart J. 24 2003 1833 1842
51. M.H. Frick, O. Elo, K. Haapa, O.P. Heinonen, P. Heinsalmi, P. Helo, J.K. Huttunen, P. Kaitaniemi, P. Koskinen, and V. Manninen Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease N. Engl. J. Med. 317 1987 1237 1245
52. R. Fux, K. Morike, U.F. Gundel, R. Hartmann, and C.H. Gleiter Ezetimibe and statin-associated myopathy Ann. Intern. Med. 140 2004 671 672
53. A.L. Garcia-Otin, F. Civeira, R. Aristegui, C. Diaz, D. Recalde, J.M. Sol, X. Masramon, G. Hernandez, and M. Pocovi Allelic polymorphism-491A/T in apo E gene modulates the lipid-lowering response in combined hyperlipidemia treatment Eur. J. Clin. Investig. 32 2002 421 428
54. L.U. Gerdes, C. Gerdes, K. Kervinen, M. Savolainen, I.C. Klausen, P.S. Hansen, Y.A. Kesaniemi, and O. Faergeman The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study Circulation 101 2000 1366 1371
55. G. Ghirlanda, A. Oradei, A. Manto, S. Lippa, L. Uccioli, S. Caputo, A.V. Greco, and G.P. Littarru Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study J. Clin. Pharmacol. 33 1993 226 229
56. L.W. Gibbons, V. Gonzalez, N. Gordon, and S. Grundy The prevalence of side effects with regular and sustained-release nicotinic acid Am. J. Med. 99 1995 378 385
57. D.F. Gray, H. Bundgaard, P.S. Hansen, K.A. Buhagiar, A.S. Mihailidou, W. Jessup, K. Kjeldsen, and H.H. Rasmussen HMG CoA reductase inhibition reduces sarcolemmal Na(+)-K(+) pump density Cardiovasc. Res. 47 2000 329 335
58. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr., L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith Jr., and N.J. Stone Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J. Am. Coll. Cardiol. 44 2004 720 732
59. E.C. Guzman, M.H. Hirata, E.C. Quintao, and R.D. Hirata Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease Clin. Chem. Lab. Med. 38 2000 731 736
60. G.F. Hoffmann, C. Charpentier, E. Mayatepek, J. Mancini, M. Leichsenring, K.M. Gibson, P. Divry, M. Hrebicek, W. Lehnert, and K. Sartor Clinical and biochemical phenotype in 11 patients with mevalonic aciduria Pediatrics 91 1993 915 921
61. J.D. Horton, and I. Shimomura Sterol regulatory element-binding proteins: activators of cholesterol and fatty acid biosynthesis Curr. Opin. Lipidol. 10 1999 143 150
62. E. Hustert, M. Haberl, O. Burk, R. Wolbold, Y.Q. He, K. Klein, A.C. Nuessler, P. Neuhaus, J. Klattig, R. Eiselt, I. Koch, A. Zibat, J. Brockmoller, J.R. Halpert, U.M. Zanger, and L. Wojnowski The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 2001 773 779
63. C. Ishikawa, H. Ozaki, T. Nakajima, T. Ishii, S. Kanai, S. Anjo, K. Shirai, and I. Inoue A frameshift variant of CYP2C8 was identified in a patient who suffered from rhabdomyolysis after administration of cerivastatin J. Hum. Genet. 49 2004 582 585
64. L. Jeu, and J.W. Cheng Pharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitor Clin. Ther. 25 2003 2352 2387
65. K. Johansen, H. Theorell, J. Karlsson, B. Diamant, and K. Folkers Coenzyme Q10, alpha-tocopherol and free cholesterol in HDL and LDL fractions Ann. Med. 23 1991 649 656
66. P.H. Jones, and M.H. Davidson Reporting rate of rhabdomyolysis with fenofibrate+statin versus gemfibrozil + any statin Am. J. Cardiol. 95 2005 120 122
67. J.W. Jukema, A.J. van Boven, B. Groenemeijer, A.H. Zwinderman, J.H. Reiber, A.V. Bruschke, J.A. Henneman, G.P. Molhoek, T. Bruin, H. Jansen, E. Gagne, M.R. Hayden, and J.J. Kastelein The Asp9 Asn mutation in the lipoprotein lipase gene is associated with increased progression of coronary atherosclerosis. REGRESS Study Group, Interuniversity Cardiology Institute, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study Circulation 94 1996 1913 1918
68. K. Kajinami, M.E. Brousseau, C. Nartsupha, J.M. Ordovas, and E.J. Schaefer ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin J. Lipid Res. 45 2004 653 656
69. K. Kajinami, M.E. Brousseau, J.M. Ordovas, and E.J. Schaefer CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia Am. J. Cardiol. 93 2004 104 107
70. K. Kajinami, M.E. Brousseau, J.M. Ordovas, and E.J. Schaefer Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL-cholesterol-lowering response to atorvastatin Atherosclerosis 175 2004 287 293
71. K. Kajinami, M.E. Brousseau, J.M. Ordovas, and E.J. Schaefer Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner Am. J. Cardiol. 93 2004 1046 1050
72. K. Kajinami, N. Takekoshi, M.E. Brousseau, and E.J. Schaefer Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management Atherosclerosis 177 2004 219 234
73. K. Kajinami, M.E. Brousseau, S. Lamon-Fava, J.M. Ordovas, and E.J. Schaefer Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism Atherosclerosis 178 2005 331 338
74. F. Karpe, and K.N. Frayn The nicotinic acid receptor-a new mechanism for an old drug Lancet 363 2004 1892 1894
75. J. Kirchheiner, D. Kudlicz, C. Meisel, S. Bauer, I. Meineke, I. Roots, and J. Brockmoller Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S- fluvastatin in healthy volunteers Clin. Pharmacol. Ther. 74 2003 186 194
76. K.T. Kivisto, M. Niemi, E. Schaeffeler, K. Pitkala, R. Tilvis, M.F. Fromm, M. Schwab, M. Eichelbaum, and T. Strandberg Lipid-lowering response to statins is affected by CYP3A5 polymorphism Pharmacogenetics 14 2004 523 525
77. R.H. Knopp Drug treatment of lipid disorders N. Engl. J. Med. 341 1999 498 511
78. R.H. Knopp, H. Gitter, T. Truitt, H. Bays, C.V. Manion, L.J. Lipka, A.P. Lebeaut, R. Suresh, B. Yang, and E.P. Veltri Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia Eur. Heart J. 24 2003 729 741
79. W. Kramer, F. Girbig, D. Corsiero, A. Pfenninger, W. Frick, M. Rhein, W. Wendler, F. Lottspeich, E.O. Hochleitner, E. Orso, and G. Schmitz Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor Ezetimibe in the enterocyte brush border membrane J. Biol. Chem. 280 2004 1306 1320
80. R.A. Kreisberg, and A. Oberman Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies J. Clin. Endocrinol. Metab. 87 2002 423 437
81. J.A. Kuivenhoven, J.W. Jukema, A.H. Zwinderman, P. de Knijff, R. McPherson, A.V. Bruschke, K.I. Lie, and J.J. Kastelein The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group N. Engl. J. Med. 338 1998 86 93
82. T.A. Kunnas, T. Lehtimaki, R. Laaksonen, E. Ilveskoski, T. Janatuinen, R. Vesalainen, P. Nuutila, P.J. Karhunen, J. Knuuti, and S.T. Nikkari Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study J. Mol. Med. 80 2002 802 807
83. H. Kusuhara, H. Suzuki, and Y. Sugiyama The role of P-glycoprotein and canalicular multispecific organic anion transporter in the hepatobiliary excretion of drugs J. Pharm. Sci. 87 1998 1025 1040
84. C. Kyrklund, J.T. Backman, K.T. Kivisto, M. Neuvonen, J. Laitila, and P.J. Neuvonen Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate Clin. Pharmacol. Ther. 69 2001 340 345
85. C. Kyrklund, J.T. Backman, M. Neuvonen, and P.J. Neuvonen Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance Clin. Pharmacol. Ther. 73 2003 538 544
86. C. Lahoz, R. Pena, J.M. Mostaza, J. Jimenez, E. Subirats, X. Pinto, M. Taboada, and A. Lopez-Pastor Apo A-I promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy Atherosclerosis 168 2003 289 295
87. J.C. LaRosa, J. He, and S. Vupputuri Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA 282 1999 2340 2346
88. H. Ledmyr, A.D. McMahon, E. Ehrenborg, L.B. Nielsen, M. Neville, H. Lithell, P.W. MacFarlane, C.J. Packard, and F. Karpe The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease Circulation 109 2004 2279 2284
89. T. Lehtimaki, R. Laaksonen, T. Janatuinen, R. Vesalainen, P. Nuutila, K. Mattila, E. Ilveskoski, M. Luomala, P. Saikku, J. Knuuti, and M. Hurme Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men Pharmacogenetics 13 2003 633 639
90. P. Libby, and M. Aikawa Stabilization of atherosclerotic plaques: new mechanisms and clinical targets Nat. Med. 8 2002 1257 1262
91. S.F. London, K.F. Gross, and S.P. Ringel Cholesterol-lowering agent myopathy (CLAM) Neurology 41 1991 1159 1160
92. S. Lutucuta, C.M. Ballantyne, H. Elghannam, A.M. Gotto Jr., and A.J. Marian Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy Circ. Res. 88 2001 969 973
93. A.H. Maitland-van der Zee, O.H. Klungel, B.H. Stricker, W.M. Monique Verschuren, J.J. Kastelein, H.G. Leufkens, and A. de Boer Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors Atherosclerosis 163 2002 213 222
94. A.H. Maitland-van der Zee, B.H. Stricker, O.H. Klungel, A.K. Mantel-Teeuwisse, J.J. Kastelein, A. Hofman, H.G. Leufkens, C.M. van Duijn, and A. de Boer Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes Pharmacogenetics 13 2003 219 223
95. S. Malik, and M.L. Kashyap Niacin, lipids, and heart disease Curr. Cardiol. Rep. 5 2003 470 476
96. R. Malin, R. Laaksonen, J. Knuuti, T. Janatuinen, R. Vesalainen, P. Nuutila, and T. Lehtimaki Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol Pharmacogenetics 11 2001 625 633
97. A.J. Marian, F. Safavi, L. Ferlic, J.K. Dunn, A.M. Gotto, and C.M. Ballantyne Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the Lipoprotein and Coronary Atherosclerosis Study J. Am. Coll. Cardiol. 35 2000 89 95
98. D.J. Maron, S. Fazio, and M.F. Linton Current perspectives on statins Circulation 101 2000 207 213
99. P.G. McGovern, J.S. Pankow, E. Shahar, K.M. Doliszny, A.R. Folsom, H. Blackburn, and R.V. Luepker Recent trends in acute coronary heart disease-mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators N. Engl. J. Med. 334 1996 884 890
100. M. Meriane, P. Roux, M. Primig, P. Fort, and C. Gauthier-Rouviere Critical activities of Rac1 and Cdc42Hs in skeletal myogenesis: antagonistic effects of JNK and p38 pathways Mol. Biol. Cell 11 2000 2513 2528
101. D.B. Miller, and J.D. Spence Clinical pharmacokinetics of fibric acid derivatives (fibrates) Clin. Pharmacokinet. 34 1998 155 162
102. B. Moosmann, and C. Behl Selenoprotein synthesis and side-effects of statins Lancet 363 2004 892 894
103. A.B. Mulder, H.J. van Lijf, M.A. Bon, F.A. van den Bergh, D.J. Touw, C. Neef, and I. Vermes Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin Clin. Pharmacol. Ther. 70 2001 546 551
104. D. Nakai, R. Nakagomi, Y. Furuta, T. Tokui, T. Abe, T. Ikeda, and K. Nishimura Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes J. Pharmacol. Exp. Ther. 297 2001 861 867
105. P. Nestel, L. Simons, P. Barter, P. Clifton, D. Colquhoun, I. Hamilton-Craig, K. Sikaris, and D. Sullivan A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin Atherosclerosis 129 1997 231 239
106. M. Niemi, E. Schaeffeler, T. Lang, M.F. Fromm, M. Neuvonen, C. Kyrklund, J.T. Backman, R. Kerb, M. Schwab, P.J. Neuvonen, M. Eichelbaum, and K.T. Kivisto High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) Pharmacogenetics 14 2004 429 440
107. Y. Nishizato, I. Ieiri, H. Suzuki, M. Kimura, K. Kawabata, T. Hirota, H. Takane, S. Irie, H. Kusuhara, Y. Urasaki, A. Urae, S. Higuchi, K. Otsubo, and Y. Sugiyama Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics Clin. Pharmacol. Ther. 73 2003 554 565
108. J.P. Ojala, E. Helve, C. Ehnholm, K. Aalto-Setala, K.K. Kontula, and M.J. Tikkanen Effect of apolipoprotein E polymorphism and XbaI polymorphism of apolipoprotein B on response to lovastatin treatment in familial and non-familial hypercholesterolaemia J. Intern. Med. 230 1991 397 405
109. F.H. O'Neill, D.D. Patel, B.L. Knight, C.K. Neuwirth, M. Bourbon, A.K. Soutar, G.W. Taylor, G.R. Thompson, and R.P. Naoumova Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia Arterioscler. Thromb. Vasc. Biol. 21 2001 832 837
110. J.M. Ordovas, J. Lopez-Miranda, F. Perez-Jimenez, C. Rodriguez, J.S. Park, T. Cole, and E.J. Schaefer Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy Atherosclerosis 113 1995 157 166
111. J.M. Ordovas, L.A. Cupples, D. Corella, J.D. Otvos, D. Osgood, A. Martinez, C. Lahoz, O. Coltell, P.W. Wilson, and E.J. Schaefer Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study Arterioscler. Thromb. Vasc. Biol. 20 2000 1323 1329
112. R. Paoletti, A. Corsini, and S. Bellosta Pharmacological interactions of statins Atheroscler. Suppl. 3 2002 35 40
113. J. Pedro-Botet, E.J. Schaefer, R.G. Bakker-Arkema, D.M. Black, E.M. Stein, D. Corella, and J.M. Ordovas Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner Atherosclerosis 158 2001 183 193
114. N. Petit, A. Lescure, M. Rederstorff, A. Krol, B. Moghadaszadeh, U.M. Wewer, and P. Guicheney Selenoprotein N: an endoplasmic reticulum glycoprotein with an early developmental expression pattern Hum. Mol. Genet. 12 2003 1045 1053
115. P.S. Phillips, R.H. Haas, S. Bannykh, S. Hathaway, N.L. Gray, B.J. Kimura, G.D. Vladutiu, and J.D. England Statin-associated myopathy with normal creatine kinase levels Ann. Intern. Med. 137 2002 581 585
116. L.R. Pierce, D.K. Wysowski, and T.P. Gross Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy JAMA 264 1990 71 75
117. M.E. Poynter, and R.A. Daynes Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging J. Biol. Chem. 273 1998 32833 32841
118. C.R. Pullinger, C. Eng, G. Salen, S. Shefer, A.K. Batta, S.K. Erickson, A. Verhagen, C.R. Rivera, S.J. Mulvihill, M.J. Malloy, and J.P. Kane Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype J. Clin. Invest. 110 2002 109 117
119. D.J. Rader Regulation of reverse cholesterol transport and clinical implications Am. J. Cardiol. 92 2003 42J 49J
120. S.J. Robins Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Curr. Opin. Lipidol. 14 2003 575 583
121. S.D. Ross, I.E. Allen, J.E. Connelly, B.M. Korenblat, M.E. Smith, D. Bishop, and D. Luo Clinical outcomes in statin treatment trials: a meta-analysis Arch. Intern. Med. 159 1999 1793 1802
122. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, M.B. Elam, F.H. Faas, E. Linares, E.J. Schaefer, G. Schectman, T.J. Wilt, and J. Wittes Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N. Engl. J. Med. 341 1999 410 418
123. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M. Arnold, C.C. Wun, B.R. Davis, and E. Braunwald The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators N. Engl. J. Med. 335 1996 1001 1009
124. T. Sakaeda, T. Nakamura, and K. Okumura Pharmacogenetics of drug transporters and its impact on the pharmacotherapy Curr. Top. Med. Chem. 4 2004 1385 1398
125. L. Salek, S. Lutucuta, C.M. Ballantyne, A.M. Gotto Jr., and A.J. Marian Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin J. Mol. Med. 80 2002 737 744
126. G. Schonfeld The effects of fibrates on lipoprotein and hemostatic coronary risk factors Atherosclerosis 111 1994 161 174
127. C.D. Scripture, and J.A. Pieper Clinical pharmacokinetics of fluvastatin Clin. Pharmacokinet. 40 2001 263 281
128. P.S. Sever, B. Dahlof, N.R. Poulter, H. Wedel, G. Beevers, M. Caulfield, R. Collins, S.E. Kjeldsen, A. Kristinsson, G.T. McInnes, J. Mehlsen, M. Nieminen, E. O'Brien, and J. Ostergren Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
129. A. Shek, and M.J. Ferrill Statin-fibrate combination therapy Ann. Pharmacother. 35 2001 908 917
130. J. Shepherd, C.J. Packard, S. Bicker, T.D. Lawrie, and H.G. Morgan Cholestyramine promotes receptor-mediated low-density-lipoprotein catabolism N. Engl. J. Med. 302 1980 1219 1222
131. J. Shepherd, S.M. Cobbe, I. Ford, C.G. Isles, A.R. Lorimer, P.W. MacFarlane, J.H. McKillop, and C.J. Packard Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group N. Engl. J. Med. 333 1995 1301 1307
132. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema, A.M. Kamper, P.W. MacFarlane, A.E. Meinders, J. Norrie, C.J. Packard, I.J. Perry, D.J. Stott, B.J. Sweeney, C. Twomey, and R.G. Westendorp Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
133. G. Siest, E. Jeannesson, H. Berrahmoune, S. Maumus, J.B. Marteau, S. Mohr, and S. Visvikis Pharmacogenomics and drug response in cardiovascular disorders Pharmacogenomics 5 2004 779 802
134. H. Sinzinger, R. Wolfram, and B.A. Peskar Muscular side effects of statins J. Cardiovasc. Pharmacol. 40 2002 163 171
135. E.A. Stein New statins and new doses of older statins Curr. Atheroscler. Rep. 3 2001 14 18
136. K.L. Steinmetz Colesevelam hydrochloride Am. J. Health-Syst. Pharm. 59 2002 932 939
137. D. Streja Combination therapy for the treatment of dyslipidemia Curr. Opin. Investig. Drugs 5 2004 306 312
138. T. Sudhop, D. Lutjohann, A. Kodal, M. Igel, D.L. Tribble, S. Shah, I. Perevozskaya, and K. Von Bergmann Inhibition of intestinal cholesterol absorption by ezetimibe in humans Circulation 106 2002 1943 1948
139. A. Takahashi-Yasuno, H. Masuzaki, T. Miyawaki, Y. Ogawa, N. Matsuoka, T. Hayashi, K. Hosoda, G. Inoue, Y. Yoshimasa, and K. Nakao Leptin receptor polymorphism is associated with serum lipid levels and impairment of cholesterol lowering effect by simvastatin in Japanese men Diabetes Res. Clin. Pract. 62 2003 169 175
140. P.D. Thompson, P. Clarkson, and R.H. Karas Statin-associated myopathy JAMA 289 2003 1681 1690
141. S. Tunaru, J. Kero, A. Schaub, C. Wufka, A. Blaukat, K. Pfeffer, and S. Offermanns PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect Nat. Med. 9 2003 352 355
142. M. Ucar, T. Mjorndal, and R. Dahlqvist HMG-CoA reductase inhibitors and myotoxicity Drug Saf. 22 2000 441 457
143. M. van Heek, C. Farley, D.S. Compton, L. Hoos, K.B. Alton, E.J. Sybertz, and H.R. Davis Jr. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663 Br. J. Pharmacol. 129 2000 1748 1754
144. F.V. van Venrooij, R.P. Stolk, J.D. Banga, T.P. Sijmonsma, A. van Tol, D.W. Erkelens, and G.M. Dallinga-Thie Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes Diabetes Care 26 2003 1216 1223
145. P.A. Walravens, C. Greene, and F.E. Frerman Lovastatin, isoprenes, and myopathy Lancet 2 1989 1097 1098
146. D.H. Walter, V. Schachinger, M. Elsner, S. Mach, S. Dimmeler, W. Auch-Schwelk, and A.M. Zeiher Statin therapy is associated with reduced restenosis rates after coronary stent implantation in carriers of the Pl(A2)allele of the platelet glycoprotein IIIa gene Eur. Heart J. 22 2001 587 595
147. J. Wang, D.J. Freeman, S.M. Grundy, D.M. Levine, R. Guerra, and J.C. Cohen Linkage between cholesterol 7alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations J. Clin. Invest. 101 1998 1283 1291
148. J.S. Wang, M. Neuvonen, X. Wen, J.T. Backman, and P.J. Neuvonen Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes Drug Metab. Dispos. 30 2002 1352 1356
149. T.D. Wang, W.J. Chen, J.W. Lin, C.C. Cheng, M.F. Chen, and Y.T. Lee Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles Atherosclerosis 170 2003 315 323
150. B.R. Winkelmann, M.M. Hoffmann, M. Nauck, A.M. Kumar, K. Nandabalan, R.S. Judson, B.O. Boehm, A.R. Tall, G. Ruano, and W. Marz Haplotypes of the cholesteryl ester transfer protein gene predict lipid-modifying response to statin therapy Pharmacogenomics J. 3 2003 284 296
151. A. Zambon, S.S. Deeb, B.G. Brown, J.E. Hokanson, and J.D. Brunzell Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment Circulation 103 2001 792 798
152. C. Zellner, C.R. Pullinger, B.E. Aouizerat, P.H. Frost, P.Y. Kwok, M.J. Malloy, and J.P. Kane Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors Human Mutat. 25 2005 18 21
153. F.L. Zhang, and P.J. Casey Protein prenylation: molecular mechanisms and functional consequences Annu. Rev. Biochem. 65 1996 241 269
154. F. Zito, G.D. Lowe, A. Rumley, A.D. McMahon, and S.E. Humphries Association of the factor XII 46C > T polymorphism with risk of coronary heart disease (CHD) in the WOSCOPS study Atherosclerosis 165 2002 153 158